J&J wraps up potential $1B buyout of Aragon Pharmaceuticals

08/20/2013 | PharmaTimes (U.K.) · San Diego Business Journal

Johnson & Johnson has finalized its purchase of Aragon Pharmaceuticals, which is developing a potential treatment for prostate cancer, for $650 million plus $350 million in potential milestone fees. The acquisition gives J&J access to Aragon's androgen receptor antagonist program, including ARN-509, a drug candidate for castration-resistant prostate cancer. The deal "strengthens our prostate cancer pipeline with a second-generation, potentially best-in-class compound," said Peter Lebowitz, J&J's global therapeutic area head of oncology.

View Full Article in:

PharmaTimes (U.K.) · San Diego Business Journal

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Life Sciences Lawyer (3-5 years exp)
Ropes & Gray LLP
Boston, MA; San Francisco, CA; Silicon Valley, CA, MA
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Health Services Researcher
AARP
Washington, DC
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO